Published Erratum Epublish
PubMed: 41487912 DOI: 10.7150/ijbs.128368
Erratum: Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma: Erratum.
Int J Biol Sci 21(15):7120-7122
Authors: Bo Wang, Fang-Zheng Qi, Ping Chen, Luo-Meng Qian, Hui-Shan Su, Yang Wang, Chen-Hui Wang, Ya-Xin Hou, Qing Zhang, Ding Li, Zhe-Sheng Chen, Si-He Zhang
Affiliations
- Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
- National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, NY, 11439, USA.
Abstract
[This corrects the article DOI: 10.7150/ijbs.92211.].
MeSH
Carcinoma, Hepatocellular, Hypoxia, Therapeutics, Prodrugs